Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Conclusion: Both ruxolitinib and tofacitinib could be considered effective and well-tolerated treatments for extensive AA.Dermatology (Source: Dermatology)
Source: Dermatology - December 19, 2018 Category: Dermatology Source Type: research
Alopecia areata: A multifactorial autoimmune condition.
Abstract
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/or total loss of all body hair (Alopecia universalis). The rapid rate of hair loss and disfiguration caused by the condition causes anxiety on patients and increases the risks of developing psychological and psychiatric complications. Hair loss in alopecia areata is caused by lymphocytic infiltrations around the hair follicles and IFN-γ. IgG anti...
Source: Journal of Autoimmunity - December 15, 2018 Category: Allergy & Immunology Authors: Simakou T, Butcher JP, Reid S, Henriquez FL Tags: J Autoimmun Source Type: research
Living with alopecia areata: An online qualitative survey study.
CONCLUSIONS: Findings suggest that negative cultural meanings of hair and hair loss are pervasive and may drive social avoidance and camouflage behaviours in people with AA. Normalising social interactions with healthcare practitioners, significant others and peers were cited as pivotal to positive adjustment. Support groups and online forums were highly valued particularly as few had been offered specialist psychological support. Future research should develop and evaluate psychological support to address the specific challenges of living with AA. This article is protected by copyright. All rights reserved.
PMID: ...
Source: The British Journal of Dermatology - November 30, 2018 Category: Dermatology Authors: Davey L, Clarke V, Jenkinson E Tags: Br J Dermatol Source Type: research
Psoriasis in a cohort of patients with common variable immunodeficiency.
This article is protected by copyright. All rights reserved.
PMID: 30414274 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - November 10, 2018 Category: Dermatology Authors: Megna M, Pecoraro A, Balato N, Villani A, Crescenzi L, Balato A, Spadaro G Tags: Br J Dermatol Source Type: research
Psoriasis in a cohort of patients with common variable immunodeficiency
This article is protected by copyright. All rights reserved. (Source: British Journal of Dermatology)
Source: British Journal of Dermatology - November 10, 2018 Category: Dermatology Authors: M. Megna,
A. Pecoraro,
N. Balato,
A. Villani,
L. Crescenzi,
A. Balato,
G. Spadaro Tags: Research Letter Source Type: research
Treatment of alopecia areata: An Australian expert consensus statement.
Abstract
Alopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. While 40% of all affected individuals only ever get one patch and will achieve a spontaneous complete durable remission within 6 months, 27% will develop additional patches but still achieve complete durable remission within 12 months and 33% will develop chronic AA. Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop alopecia totalis and 15% will develop alopecia u...
Source: The Australasian Journal of Dermatology - November 8, 2018 Category: Dermatology Authors: Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, Joseph S, Chitreddy V, Gunatheesan S, Sindhu K, Sharma P, Green J, Eisman S, Yip L, Jones L, Sinclair R Tags: Australas J Dermatol Source Type: research
Treatment of alopecia areata: An Australian expert consensus statement
AbstractAlopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. While 40% of all affected individuals only ever get one patch and will achieve a spontaneous complete durable remission within 6 months, 27% will develop additional patches but still achieve complete durable remission within 12 months and 33% will develop chronic AA. Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop al opecia totalis and 15% will develop alopecia universalis. The ...
Source: Australasian Journal of Dermatology - November 8, 2018 Category: Dermatology Authors: William C Cranwell,
Vivien WY Lai,
Louise Photiou,
Nekma Meah,
Dmitri Wall,
Deepani Rathnayake,
Shobha Joseph,
Vijaya Chitreddy,
Shyamalar Gunatheesan,
Kamaldeep Sindhu,
Pooja Sharma,
Jack Green,
Samantha Eisman,
Leona Yip,
Leslie Jones,
Ro Tags: Consensus Article Source Type: research
Seasonal patterns in alopecia areata, totalis, and universalis
To the Editor: Although seasonal patterns of pediatric alopecia areata (AA), totalis (AT), and universalis (AU) have been suspected clinically, there is limited research about whether disease flares follow a temporal pattern.1-3 Patients and families report increased hair loss during the winter, with cycles of regrowth in summer months. Through retrospective review of medical records, we sought to identify whether AA, AT, and AU flares show seasonal variation in pediatric patients and to characterize temporal patterns. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - October 12, 2018 Category: Dermatology Authors: Elana Putterman, Leslie Castelo-Soccio Tags: Research letter Source Type: research
Hair Regrowth After Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab
This case report describes hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. (Source: JAMA Dermatology)
Source: JAMA Dermatology - October 10, 2018 Category: Dermatology Source Type: research
Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study.
In conclusion, oral tofacitinib was more effective than diphenylcyclopropenone immunotherapy and more tolerable than conventional oral treatment after 6 months of treatment.
PMID: 30281139 [PubMed - as supplied by publisher] (Source: Acta Dermato-Venereologica)
Source: Acta Dermato-Venereologica - October 3, 2018 Category: Dermatology Authors: Shin JW, Huh CH, Kim MW, Lee JS, Kwon O, Cho S, Park HS Tags: Acta Derm Venereol Source Type: research
Is methotrexate an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? A critically appraised topic
British Journal of Dermatology,Volume 179, Issue 3, Page e147-e147, September 2018. (Source: British Journal of Dermatology)
Source: British Journal of Dermatology - September 17, 2018 Category: Dermatology Authors: R. Browne
,
L. Stewart
,
H.C. Williams Source Type: research
Systemic treatments for alopecia areata: A systematic review.
Abstract
A range of systemic treatments are used for alopecia areata with variable evidence supporting efficacy. In this systematic review, we evaluated the evidence surrounding systemic treatments for alopecia areata, alopecia totalis and alopecia universalis. A systematic search was conducted of the peer-reviewed literature published between 1946 and March 2018 via Medline, Embase, Amed, the Cochrane Central Register of Controlled Trials, PsychINFO and Lilacs. All randomised controlled trials (RCTs) that evaluated the effectiveness of systemic treatments for individuals with alopecia areata, totalis or u...
Source: The Australasian Journal of Dermatology - September 6, 2018 Category: Dermatology Authors: Lai VWY, Chen G, Gin D, Sinclair R Tags: Australas J Dermatol Source Type: research
LB1485 Prevalence of alopecia areata in the United States from a large cross-sectional survey
The prevalence of alopecia areata (AA) in the United States (US) is not well known. A commonly cited self-reported period prevalence of 0.16% is sourced from the National Health and Nutrition Examination Survey (NHANES) over 40 years ago (1971-74). Other studies focused on alopecia totalis (AT; 100% scalp hair loss) and alopecia universalis (AU; complete body hair loss). We administered an online cross-sectional survey to a representative sample (n=45,016 aged ≥11years) of the US population with respect to age (11-17 years represented by parent proxy), gender, race, income, and region. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - August 21, 2018 Category: Dermatology Authors: A. Mostaghimi, B. Michael, M. Udall, K. Anastassopoulos, J. Cappelleri, S. Daniel, P. Wahl, P. Chander, J. Lapthorn, L. Chen, E. Peeva Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
The efficacy and safety of tofacitinib in patients with alopecia totalis
Background: Alopecia areata (AA) is a common hair loss condition that is characterized by acute onset of nonscarring hair loss in usually sharply defined areas ranging from small patches to extensive or less frequently diffuse involvement. In a mouse model of AA, CD8+NKG2D+ T cells were shown to be central in AA, causing up-regulation of interleukin-15 in hair follicles and ultimately production of INF- γ, which targets the hair follicle for attack. The common gamma chain (γc; expressed by IL-15R) signals through Janus kinase (JAK) 1 and 3, whereas INF-γ through JAK 1 and 2. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - August 2, 2018 Category: Dermatology Source Type: research
Multi-Concentration Level Patch Test Guided Diphenyl Cyclopropenone (DPCP) Treatment in Alopecia Totalis or Alopecia Universalis.
Conclusion: Patch test guided DPCP therapy may be a new regimen for alopecia areata treatment because of shortening treatment duration without increasing complications.
PMID: 29911776 [PubMed - in process] (Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet)
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - June 21, 2018 Category: General Medicine Tags: J Med Assoc Thai Source Type: research
